Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
129 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 7, 1, 20, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development A1M Pharma AB Alloksys Life Sciences BV Am-Pharma BV Angion Biomedica Corp Atox Bio Ltd Cellmid Ltd Complexa Inc DiaMedica Therapeutics Inc DURECT Corp Evotec AG Exponential Biotherapies Inc G1 Therapeutics Inc Kringle Pharma Inc Mitotech SA NephroGenex Inc Quark Pharmaceuticals Inc Regulus Therapeutics Inc SBI Pharmaceuticals Co Ltd Spherium Biomed SL STATegics Inc Stealth BioTherapeutics Inc Torrent Pharmaceuticals Ltd Xigen SA Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile Product Description Mechanism Of Action R&D Progress A1M-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile Product Description Mechanism Of Action R&D Progress BB-3 - Drug Profile Product Description Mechanism Of Action R&D Progress brimapitide - Drug Profile Product Description Mechanism Of Action R&D Progress CAB-101 - Drug Profile Product Description Mechanism Of Action R&D Progress CXA-10 - Drug Profile Product Description Mechanism Of Action R&D Progress DM-199 - Drug Profile Product Description Mechanism Of Action R&D Progress Drug for Kidney Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress DUR-928 - Drug Profile Product Description Mechanism Of Action R&D Progress EA-230 - Drug Profile Product Description Mechanism Of Action R&D Progress elamipretide - Drug Profile Product Description Mechanism Of Action R&D Progress G-1T100182 - Drug Profile Product Description Mechanism Of Action R&D Progress K-1042 - Drug Profile Product Description Mechanism Of Action R&D Progress K-1052 - Drug Profile Product Description Mechanism Of Action R&D Progress KP-100IT - Drug Profile Product Description Mechanism Of Action R&D Progress MG-53 - Drug Profile Product Description Mechanism Of Action R&D Progress NOXD-21 - Drug Profile Product Description Mechanism Of Action R&D Progress NYK-1341 - Drug Profile Product Description Mechanism Of Action R&D Progress Plastomitin - Drug Profile Product Description Mechanism Of Action R&D Progress Pyridoxamine Dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress QPI-1002 - Drug Profile Product Description Mechanism Of Action R&D Progress R-190 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Human Alkaline Phosphatase - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile Product Description Mechanism Of Action R&D Progress reltecimod sodium - Drug Profile Product Description Mechanism Of Action R&D Progress RLS-003 - Drug Profile Product Description Mechanism Of Action R&D Progress RMC-035 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile Product Description Mechanism Of Action R&D Progress SP-15016 - Drug Profile Product Description Mechanism Of Action R&D Progress STSE-15 - Drug Profile Product Description Mechanism Of Action R&D Progress SUL-138 - Drug Profile Product Description Mechanism Of Action R&D Progress TRC-160334 - Drug Profile Product Description Mechanism Of Action R&D Progress TTX-332 - Drug Profile Product Description Mechanism Of Action R&D Progress Vanadis-03 - Drug Profile Product Description Mechanism Of Action R&D Progress Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones Featured News & Press Releases Jun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGard May 22, 2017: AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase Mar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study Feb 10, 2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies Jan 31, 2017: Angion Biomedica Phase 2 "GUARD" Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program Dec 20, 2016: Silence Therapeutics Announces Quark Arbitration Resolution Dec 09, 2016: ROSGard shows renal protective effect during radiation therapy Nov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016 Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002 Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for "Most Innovative Clinical Trial Design" Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Therapeutics Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Regulus Therapeutics Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
